AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 41 min read$MIRM

HC Wainwright & Co. maintains Mirum Pharmaceuticals at Buy, raises price target to $202 from $200

HC Wainwright & Co. kept its Buy rating on Mirum Pharmaceuticals and increased its price target to $202 from $200. This implies a 132.1% upside from the Nov 3 close of $87.03. Other recent analyst targets for the company range from $145 to $160.

Original reporting
tradingview.com
Published Nov 4, 2026, 12:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. maintains Mirum Pharmaceuticals at Buy, raises price target to $202 from $200 — source image
Source · tradingview.com
Decision brief

The 30-second read

$MIRMBullishMed
01

Why it matters

Analyst price target upgrades can trigger short-term buying, but biotech valuations remain volatile pending clinical outcomes.

02

Market read

The upgrade may generate modest buying interest in MIRM, with limited broader market effect.

03

What to watch

Potential dilution from future financing rounds could offset upside.

Relevance 7/10Novelty 6/10Timing: today

Background

Mirum Pharmaceuticals is a Nasdaq-listed biotech focused on rare disease therapies.

Company-level read

Ticker impact

$MIRMBullishMedium confidence
Context

HC Wainwright raised Mirum Pharmaceuticals' price target to $202 from $200, indicating a fresh analyst upgrade.

Expected impact

potential upward pressure as investors price in the higher target

Evidence & confidence

Analyst upgrades typically lead to short-term buying interest, especially for a small-cap biotech with a recent price target increase.

Market effects

Sector

May lift sentiment in the biotech sector as peers see similar analyst optimism.

Regional

Limited to US markets where Mirum trades.

Global

Low; impact confined to Mirum and possibly related biotech stocks.

Counterpoint

What could challenge this read

The target raise could be premature if upcoming trial data disappoints.

Key entities

  • Company
    Mirum Pharmaceuticals

    Biotech firm receiving a new price target.

  • Research Firm
    HC Wainwright & Co.

    Analyst firm that raised the price target.

Read at source← All news

Related articles

NOV 4
$MIRMMed

Citizens raises Mirum Pharmaceuticals price target on pipeline progress

Citizens raised its price target for Mirum Pharmaceuticals (MIRM) to $167 from $144, citing Livmarli's growth and a diversified pipeline. The company reported 44% revenue growth and 81.7% gross margin. Mirum's Q3 2026 revenue of $185.7M beat estimates, though it posted a wider-than-expected loss per share. The stock has a Strong Buy consensus with targets ranging from $118 to $200.

investing.com2 min
NOV 4
$MIRMMed

Mirum Pharmaceuticals Inc (MIRM) Q3 2026 Earnings Call Highlights: Raised Guidance

Mirum Pharmaceuticals (MIRM) raised its full-year guidance, citing broad-based growth, with adult PFIC as the biggest driver. Q3 saw elevated R&D expenses and minimal Takeda purchases of Livmarli. The company faces regulatory uncertainty for Belixabat and potential revenue headwinds. Management expects continued quarterly revenue growth of $10M-$15M through 2027, with key data readouts planned for Q1 2027.

finance.yahoo.com3 min
NOV 4
$MIRMHighAI 8/10

Mirum Pharmaceuticals Q3 Earnings Call Highlights

Mirum Pharmaceuticals reported Q3 revenue growth of $10M-$15M, expecting this trend to continue through 2027. ATEBRIOZ, approved in September, began U.S. launch with positive early feedback. The company anticipates multiple regulatory submissions in 2027. Mirum ended Q3 with $500M in cash and expects R&D expenses to decline to 10% of revenue long-term.

finance.yahoo.com3 min
NOV 3
$MIRMMedAI 8/10

Mirum Pharmaceuticals Q3FY26 Results: Sales rise 40%, guidance beats estimates

Mirum Pharmaceuticals reported Q3FY26 net product sales of $186M, up 40% YoY. The company raised full-year guidance to $715M-$720M, beating estimates. Livmarli drove growth, with adult PFIC as a key driver. Operating expenses were $245M, with R&D at 50% of revenue. Cash position is ~$500M. The company plans several regulatory milestones and expects cash flow positivity next year.

scanx.trade5 min
NOV 3
$MIRMHighAI 9/10

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update – Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million – Received U.S. FDA approval of and launched ATEBR

SEC EDGAR 8-K2 min